Ameritas Advisory Services LLC Takes Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Posted by Defense World Staff on Jul 23rd, 2023

Ameritas Advisory Services LLC purchased a new position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,908 shares of the company’s stock, valued at approximately $355,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. SG Americas Securities LLC grew its holdings in shares of Reata Pharmaceuticals by 23.1% during the 1st quarter. SG Americas Securities LLC now owns 8,558 shares of the company’s stock worth $778,000 after acquiring an additional 1,606 shares during the period. Handelsbanken Fonder AB grew its stake in Reata Pharmaceuticals by 13.8% in the first quarter. Handelsbanken Fonder AB now owns 8,232 shares of the company’s stock worth $748,000 after purchasing an additional 1,000 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Reata Pharmaceuticals by 34.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 435 shares of the company’s stock worth $40,000 after purchasing an additional 112 shares in the last quarter. Moody Aldrich Partners LLC purchased a new position in Reata Pharmaceuticals during the first quarter valued at $4,503,000. Finally, Arizona State Retirement System boosted its holdings in shares of Reata Pharmaceuticals by 3.2% during the 1st quarter. Arizona State Retirement System now owns 7,814 shares of the company’s stock valued at $710,000 after buying an additional 239 shares in the last quarter. 73.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Reata Pharmaceuticals

In related news, SVP Andrea Loewen sold 6,750 shares of Reata Pharmaceuticals stock in a transaction on Friday, May 12th. The stock was sold at an average price of $86.26, for a total value of $582,255.00. Following the completion of the sale, the senior vice president now owns 32,007 shares of the company’s stock, valued at $2,760,923.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Michael D. Wortley sold 894 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $84.81, for a total value of $75,820.14. Following the transaction, the insider now owns 47,198 shares of the company’s stock, valued at $4,002,862.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Andrea Loewen sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $86.26, for a total transaction of $582,255.00. Following the sale, the senior vice president now owns 32,007 shares of the company’s stock, valued at $2,760,923.82. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,682 shares of company stock worth $10,758,842. Insiders own 26.80% of the company’s stock.

Reata Pharmaceuticals Trading Up 0.7 %

NASDAQ RETA opened at $110.86 on Friday. The stock has a 50-day moving average of $96.87 and a 200 day moving average of $80.09. Reata Pharmaceuticals, Inc. has a one year low of $18.47 and a one year high of $113.61.

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($3.14) earnings per share for the quarter, missing the consensus estimate of ($2.34) by ($0.80). The firm had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.73 million. Analysts anticipate that Reata Pharmaceuticals, Inc. will post -10.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on RETA. 888 reiterated a “reiterates” rating on shares of Reata Pharmaceuticals in a research note on Wednesday, June 28th. Stifel Nicolaus lifted their target price on shares of Reata Pharmaceuticals from $105.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, April 13th. Cantor Fitzgerald cut their price target on Reata Pharmaceuticals from $138.00 to $110.00 in a research note on Wednesday, May 10th. SVB Leerink upgraded Reata Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 12th. Finally, SVB Securities raised Reata Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $80.00 to $115.00 in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.90.

Reata Pharmaceuticals Company Profile

(Free Report)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.